MRSA infections in hospitals are a major issue in wound control. It’s an exciting idea. A recent article written up in Natures sister publication by Mark Blaskovitzch and colleagues at UQ shows early efficacy of anti-microbial synthetic CBD in killing staph without building resistance. Botanix pharmaceuticals (asx BOT) is about to commence a trial to see if this new antibiotic can eliminate bacterial blood infections in dialysis patients using synthetic CBD. If this tech is successful and preventing anti-biotic resistance you could see a synergy for BTM.
Ann: Webcast Recording - Investor Presentation and Update, page-13
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.04 |
Change
-0.030(1.45%) |
Mkt cap ! $1.409B | |||
| Open | High | Low | Value | Volume |
| $2.09 | $2.11 | $2.03 | $1.727M | 838.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 299194 | $2.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.04 | 1559 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |